The ionizable cationic lipid DLin-MC3-DMA is an effective vector for siRNA delivery. DLin-MC3-DMA (MC3) was discovered by Thomas Madden and Michael Hope during their exploration of novel ionizable lipids. It was used as a key component in Onpattro, the first siRNA drug approved by the FDA in 2018 (Onpattro also marks the first-ever targeted RNA-based gene therapy administered via a non-viral vector).
| Product Name | DLin-MC3-DMA |
| Chemical Name | 4-(dimethylamino)-butanoic acid, (10Z, 13Z)-1-(9Z, 12Z) -9, 12-octadecadien-1-yl-10, 13-nonadecadien-1-yl ester |
| CAS No. | 1224606-06-7 |
| NMPA CDE registration no. | / |
| USFDA DMF No. | / |
| Quality grade | Injection |
| Quality standards | manufacturer's standard |
| Molecular Formula | C43H79NO2 |
| Applications and examples | Onpattro (2018)-siRNA Delivery Vector |
| Product code | O02006 |
| Package sizes | 1g |
| Storage condition |
1. Low toxicity: DLin-MC3-DMA is a pH-responsive ionizable lipid, whereby it adopts a positive charge at low pH and has near-neutral charge at physiological pH. This means that, when forming lipid nanoparticles (LNPs) encapsulating nucleic acids under acidic conditions, it exhibits minimal positive charge density in the bloodstream, resulting in low cellular toxicity.
2. High efficiency: LNPs formed with DLin-MC3-DMA exhibit positive charge, facilitating lysosomal SiRNA escape to enhance transfection efficiency and reducing phagocytosis by macrophages.
DLin-MC3-DMA is a colorless to yellowish oily liquid with a pKa of 6.44. The functional activity of LNPs is correlated with the pKa value of the cationic lipid used. LNPs formed with DLin-MC3-DMA with a pKa of 6.2 to 6.5 exhibit higher gene-silencing activity.
If you have any questions, please don't hesitate to contact us. We're always here to help with Pharmaceutical Excipients for your business. We can provide products ranging from grams to tons. AVT is able to produce and even register the product in US FDA according to your special needs.
